Hyperion DeFi (NASDAQ:HYPD) Announces Earnings Results

Hyperion DeFi (NASDAQ:HYPD) posted its quarterly earnings data on Friday. The company reported $0.05 earnings per share for the quarter, Zacks reports. Hyperion DeFi had a negative return on equity of 525.89% and a negative net margin of 62,238.41%.The firm had revenue of $0.36 million during the quarter.

Hyperion DeFi Stock Up 0.8%

HYPD stock traded up $0.04 during midday trading on Friday, reaching $5.01. 298,614 shares of the company’s stock traded hands, compared to its average volume of 462,523. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.20. The firm’s fifty day moving average price is $8.52 and its 200-day moving average price is $7.08. Hyperion DeFi has a 52 week low of $0.85 and a 52 week high of $17.99. The company has a market cap of $34.87 million, a price-to-earnings ratio of -0.20 and a beta of 2.57.

Analyst Upgrades and Downgrades

Several research firms recently commented on HYPD. Wall Street Zen cut Hyperion DeFi from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Hyperion DeFi currently has a consensus rating of “Reduce” and a consensus target price of $2.00.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.